biotin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases expanded Disability Status Scale (EDSS)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“At month 12, the mean (±standard deviation (SD)) EDSS decreased from baseline in the MD1003 arm (−0.03 ± 0.50) but increased at the expected rate in the placebo arm (+0.13 ± 0.33, p = 0.01; Figure 3).”
Quoted verbatim from MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.. - Study
- RCT
- Participants
- 154
- Duration
- 12 months
- Dose
- 100 mg biotin orally three times daily (300 mg/day)
- Population
- Adults aged 18-75 with primary or secondary progressive multiple sclerosis, baseline EDSS 4.5-7 and disease worsening in the previous 2 years; month 12 of the double-blind phase; all patients on stable concomitant therapy allowed
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.2016PMID:27589059Industry fundedPermalink
Keep reading
- Everything the graph holds on biotin
- Every compound studied against Expanded Disability Status Scale (EDSS)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PZZCFM7BJRPW43FFVBVPKM